MTI Biotech, Incorporated
Ames, IA
- UEI
- N5NDNJL8QGA1
- CAGE
- 7DW28
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- Q3GFWSAJACN3
-
- SAM.gov registration date
- Physical address
- 2711 S Loop Dr #4400, Ames, IA 50010, USA
- Website
- mtibiotech.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Hillhurst Biopharmaceuticals, Inc. | Glendale, CA | — |
| Vasculonics Inc. | Indianapolis, IN | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Biotechnology | Temecula, CA | — |
| Covenant Therapeutics LLC | Charlottesville, VA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Cornovus Pharmaceuticals Inc. | New Haven, CT | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
MTI Biotech, Incorporated is a corporate entity registered as a for-profit Subchapter S Corporation in SAM.gov to receive federal grants and contracts. It is focused on developing therapeutic compounds and approaches for various diseases and conditions.
Through federal grant awards from agencies like the National Institutes of Health (NIH), MTI Biotech has conducted research on using the compound 2-hydroxybenzylamine (2-HOBA) for the treatment of pulmonary hypertension. The grants funded studies exploring the mechanisms by which 2-HOBA can break the vicious cycle of increased reactive oxygen species, reactive lipids, and metabolic changes that contribute to pulmonary hypertension. The work has involved testing the safety, molecular efficiency, and efficacy of 2-HOBA in reducing pulmonary vascular resistance, cytokine and biomarkers, and improving right ventricular function in various animal models and pilot human trials. MTI Biotech has also received NIH funding to investigate the efficacy of 2-HOBA and related compounds in preventing gastrointestinal inflammatory carcinogenesis, such as gastric cancer caused by Helicobacter pylori infection and colitis-associated colorectal cancer. These studies have examined the protective effects of electrophile scavengers like 2-HOBA on reducing dysplasia, carcinoma, and tumor formation in mouse and gerbil models by preventing adduct formation and DNA damage from reactive electrophiles generated during chronic inflammation.
Quick answers
Is MTI Biotech, Incorporated registered in SAM.gov?
Yes. MTI Biotech, Incorporated's SAM.gov registration is active through November 25, 2026.
What is MTI Biotech, Incorporated's most recent federal award?
MTI Biotech, Incorporated's most recent federal grant award is 2-hoba for treatment of pulmonary hypertension (R42HL158393), from National Heart Lung and Blood Institute (NIH), on September 1, 2021.
On GovTribe
See MTI Biotech, Incorporated's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors